BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207]
URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7207.htm
Number Citing Articles
1
Mi Na Kim, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang‐Hyub Han. Durability of the virological response after lamivudine discontinuation in lamivudine‐resistant patients with a complete virological response after lamivudine and adefovir combination therapyJournal of Medical Virology 2017; 89(1): 85 doi: 10.1002/jmv.24616
2
Bryan R. Cobb, Alexandra Valsamakis, Randall T. Hayden, Donna M. Wolk, Karen C. Carroll, Yi-Wei Tang. Chronic Hepatitis B, C, and DMicrobiology Spectrum 2016; 4(4) doi: 10.1128/microbiolspec.DMIH2-0025-2015
3
Lei Duan, Yang Liu, Dingyu Wu, Ting Wen, Song Huang, Xiuyun Zhu, Guangyan Sun, Guohong Yang, Yinbao Hu, Shoucui Pu, Qiangwei Zeng, Qingyu Yang. Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysisVirology Journal 2025; 22(1) doi: 10.1186/s12985-025-02922-4
4
Naruhiko Nagata, Tatehiro Kagawa, Shunji Hirose, Yoshitaka Arase, Kota Tsuruya, Kazuya Anzai, Koichi Shiraishi, Tetsuya Mine. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BBMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0454-z
5
Li Gao, Yue Hu, Xiaofeng Shi, Xin Li, Dazhi Zhang, Hong Ren. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patientsAnnals of Hepatology 2020; 19(3): 329 doi: 10.1016/j.aohep.2019.10.006
6
Kyu Sik Jung, Jun Yong Park, Young Eun Chon, Hyon-Suk Kim, Wonseok Kang, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Kwang-Hyub Han, Sang Hoon Ahn. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patientsJournal of Gastroenterology 2016; 51(8): 830 doi: 10.1007/s00535-015-1153-1
7
Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Ryo Shimizu, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Masayuki Kitano. Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with EntecavirHepatitis Research and Treatment 2017; 2017: 1 doi: 10.1155/2017/2093847
8
Bryan R. Cobb, Alexandra Valsamakis. Diagnostic Microbiology of the Immunocompromised Host2016; : 69 doi: 10.1128/9781555819040.ch3